Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

6.85USD
1 Aug 2013
Price Change (% chg)

$-0.10 (-1.44%)
Prev Close
$6.95
Open
$7.15
Day's High
$7.15
Day's Low
$6.84
Volume
422,842
Avg. Vol
1,060,947
52-wk High
$10.99
52-wk Low
$6.65

ARNA.OQ

Chart for ARNA.OQ

About

Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s... (more)

Overall

Beta: 0.17
Market Cap (Mil.): $1,513.55
Shares Outstanding (Mil.): 217.78
Dividend: --
Yield (%): --

Financials

  ARNA.OQ Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.37 -- --
ROI: -40.40 -2.58 18.76
ROE: -124.20 -2.66 19.59
Search Stocks

Arena withdraws diet drug application in Europe; shares fall

- Arena Pharmaceuticals Inc withdrew an application to market its anti-obesity drug in the European Union, sending its shares down 15 percent in after-hours trading.

02 May 2013

Competitors

  Price Change
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50
GlaxoSmithKline plc (GSK.L) 1,705.80p +20.00
Orexigen Therapeutics, Inc. (OREX.OQ) $7.69 +0.09
VIVUS, Inc. (VVUS.OQ) $15.00 +0.19

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks